FIELD: medicine.
SUBSTANCE: there is produced a two-cassette genetic plasmid-based constraint pBud-VEGF-GDNF containing DNA fragments coding VEGF and GDNF. Mononuclear cells are recovered from human blood. The recovered cells are genetically modified by pBud-VEGF-GDNF. The genetically modified cells are cultivated, concentrated, purified from a culture medium, resuspended. The genetically modified cells are analysed for quantity, concentration, viability, and the analysis results are used to calculate an optimum therapeutic dose of the genetically modified cells which is a preparation of the genetically modified cells.
EFFECT: invention allows producing a preparation with substantially improved medicinal properties.
2 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR STIMULATING NEUROGENERATION BY GENETIC MAKE-UPS | 2011 |
|
RU2459630C1 |
| METHOD OF DETERMINING BIOLOGICAL ACTIVITY OF SUBSTANCE | 2009 |
|
RU2492472C2 |
| AGENT FOR REPRESSION OF DEATH OF NEURONS IN ISCHEMIC STROKE OF BRAIN AND METHOD OF CELL-MEDIATED GENE THERAPY FOR ISCHEMIC STROKE OF BRAIN BY REPRESSION OF DEATH OF NEURONS IN ISCHEMIC STROKE OF BRAIN | 2017 |
|
RU2676701C1 |
| CODON-OPTIMISED SEQUENCES AND PHARMACEUTICAL COMPOSITION FOR RECOVERY OF BLOOD VESSELS | 2014 |
|
RU2557385C1 |
| METHOD FOR TREATING TRAUMATIC SPINAL CORD INJURY | 2021 |
|
RU2758760C1 |
| METHOD OF PERSONALIZED GENE THERAPY IN CASE THERE IS THREAT OF ISCHEMIC CEREBRAL STROKE | 2023 |
|
RU2808256C1 |
| METHOD FOR STIMULATING SPINAL CORD REGENERATION WITH GENETICALLY MODIFIED HUMAN UMBILICAL CORD BLOOD CELLS | 2013 |
|
RU2521225C2 |
| METHOD FOR PREVENTIVE GENE THERAPY FOR SUPPRESSING NEURON DEATH IN ISCHEMIC BRAIN STROKE | 2020 |
|
RU2748940C2 |
| METHOD FOR PREPARING A CELL-MEDIATED GENE THERAPY AGENT AND A CELL-MEDIATED GENE THERAPY AGENT | 2019 |
|
RU2716013C2 |
| PREPARATION FOR STIMULATING REGENERATION AND NEUROPROTECTION OF NERVE TISSUE AND METHOD OF USING SAME | 2023 |
|
RU2828544C1 |
